A multicenter prospective observational study of the effects oftirzepatide on eating behavior and treatment satisfaction in patients with type 2 diabetes

A multicenter prospective observational study of the effects oftirzepatide on eating behavior and treatment satisfaction in patients with type 2 diabetes - A multicenter prospective observational study of the effects oftirzepatide on eating behavior and treatment satisfaction in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000059453

Enrollment

Registered

2025-10-20

Start date

2023-05-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

we prescribed self-injection 2.5 mg Tirzepatide per week. The prescribing physician will determine whether to increase the dose based on side effects and treatment efficacy at intervals of 4 weeks or

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: T2DM patients who agreed on prescription of Tirzepatide

Exclusion criteria

Exclusion criteria: who disagreed Tirzepatide treatment

Design outcomes

Primary

Measure	Time frame
Changes in Eating Behavior Questionnaire before treatment and after six months.	—

Countries

Japan

Contacts

Public ContactRyoichi Ishibashi

Kimitsu Chuo Hospital Department of Medicine, Division of Diabetes, Endocrinology and Metabolism

suzukiyasutaka009@gmail.com0438-36-1071

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Sep 19, 2026